Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Metrics to compare | MRKR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKRPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.8x | −2.4x | −0.6x | |
PEG Ratio | 2.44 | 0.02 | 0.00 | |
Price/Book | 4.9x | 1.6x | 2.6x | |
Price / LTM Sales | 6.7x | 9.4x | 3.2x | |
Upside (Analyst Target) | 327.9% | 268.8% | 49.4% | |
Fair Value Upside | Unlock | 25.5% | 7.8% | Unlock |